Twist Bioscience (NASDAQ:TWST) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research report sent to investors on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $60.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the stock. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays decreased their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Stock Up 0.2 %

Shares of NASDAQ:TWST opened at $47.50 on Friday. The company’s fifty day simple moving average is $44.94 and its 200 day simple moving average is $46.63. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the sale, the senior vice president now owns 133,715 shares in the company, valued at approximately $7,046,780.50. This trade represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,787 shares of company stock valued at $4,584,508 in the last ninety days. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TWST. CWM LLC raised its holdings in Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares during the last quarter. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the 2nd quarter valued at $43,000. Finally, Calamos Advisors LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth $281,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.